Smoking Increases Progression Risk in Barrett's Esophagus

Share this article:
Smoking Increases Progression Risk in Barrett's Esophagus
Smoking Increases Progression Risk in Barrett's Esophagus

FRIDAY, Feb. 3 (HealthDay News) -- Patients with Barrett's esophagus who currently smoke have twice the risk of developing esophageal cancer compared with never smokers, according to a study published in the February issue of Gastroenterology.

Helen G. Coleman, Ph.D., from Queen's University Belfast in Northern Ireland, and colleagues examined the association between lifestyle and progression of Barrett's esophagus to neoplasia in 3,167 patients diagnosed with specialized intestinal metaplasia between 1993 and 2005.

By the end of 2008, the researchers found that 117 patients had developed esophageal high-grade dysplasia or adenocarcinomas of the esophagus or gastric cardia. The risk of progression was significantly higher in patients who currently smoked tobacco (hazard ratio, 2.03), regardless of the number of cigarettes smoked per day, compared with those who had never smoked. In contrast, alcohol consumption and body size were not associated with progression.

"Smoking tobacco increases the risk of progression to cancer or high-grade dysplasia two-fold among patients with Barrett's esophagus, compared with patients with Barrett's esophagus that have never smoked," Coleman and colleagues conclude. "Smoking cessation strategies should be considered for patients with Barrett's esophagus."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

ESMO: Herceptin may be best option for HER2 breast cancer treatment

ESMO: Herceptin may be best option for HER2+ ...

Drug should remain standard of care for HER2-positive tumors, according to new research.

ESMO: Combination treatments increase metastatic melanoma survival

ESMO: Combination treatments increase metastatic melanoma survival

Studies show improved progression-free melanoma survival for both cobimetinib combined with vemurafenib, and dabrafenib combined with trametinib.

Lung infections may lessen chance of detecting lung cancer

Lung infections may lessen chance of detecting lung ...

Certain conditions make it harder to reliably detect tumors, and regions with locally-endemic infectious lung diseases pose an added hurdle for lung cancer detection.